Compare MSAI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSAI | AYTU |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 23.4M |
| IPO Year | N/A | N/A |
| Metric | MSAI | AYTU |
|---|---|---|
| Price | $0.50 | $2.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.75 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 2.1M | 52.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,563,000.00 | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $106.56 | $47.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $0.95 |
| 52 Week High | $3.33 | $2.82 |
| Indicator | MSAI | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 60.88 |
| Support Level | $0.53 | $2.05 |
| Resistance Level | $0.64 | $2.39 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 3.35 | 78.57 |
MultiSensor AI Holdings Inc build and deploy intelligent multi-sensing platforms incorporating edge and cloud software solutions that leverage artificial intelligence (AI). It is a provider of sensing systems built around high-resolution thermal imagers, visible and acoustic imagers, as well as vibration and laser spectroscopy sensors, that perceive and measure heat, sound, vibration, and gas in industrial assets and the surrounding environment, helping companies gain insight to protect and manage their most important assets and infrastructure. It also offers a wide range of form factors for its sensor devices, including, among other form factors, small to large handheld designs with built-in displays and controls, and fixed-mounted single- and multi-sensor camera sensor systems.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.